Depression Rating News Today

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.

A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.

Last month, one of its anti-psychotic drugs received approval from the Food and Drug Administration for another indication.

Pooled data confirm the superiority of electroconvulsive therapy over ketamine for major depressive episode, but ketamines faster antidepressant effects may be a factor for some patients.

Antidepressants are the first-choice treatment for severe depression. Antidepressant use is often supplemented by psychotherapy.

How pseudo-science and the psychiatrization of the pain and struggles involved in growing up have caused more harm to young people than good.